top of page
Concrete Wall

COVID-19 Projects

PIRN is involved in the following multi-site COVID-19-related projects:

Canadian Paediatric Surveillance COVID-19 Program

The Canadian Paediatric Society (CPS) and the Canadian Paediatric Surveillance Program (CPSP) are running a weekly surveillance requests for cases related to COVID-19. The goal of this program is to report all hospitalized children under 18 with COVID-19 AND non-hospitalized children with COVID-19 and underlying chronic health conditions.

   

The surveillance program is governed by the Department of Health Act and the Public Health Agency of Canada Act. Thus does not require local ethics approval to report your cases.

  

To join, you can send an email to CPSP@cps.ca with your contact information and a member of the CPSP team will be in touch with you shortly. This is an important national public health program to be a part of as they are regularly monitoring for acute flaccid paralysis, adverse drug events and other important rare concerns of public health significance for children (even throughout the non-COVID-19 season). Currently, approximately 2800 paediatricians across the country participate. 

The International Kawasaki Disease Registry (IKDR)

The Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) 

The Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) are leading a multi-site retrospective study on SARS-CoV-2 and COVID-19 in children admitted to Canadian Hospitals.  The study aims to determine the clinical spectrum and severity of children under 18 years admitted to hospital who test positive for SARS-CoV-2 across Canada.  The study is unfunded, and relies on local staff to extract data. The principal investigator is Dr. Marie-Astrid Lefebvre from Montreal, and the director of PICNIC is Dr. Joan Robinson in Edmonton.  The group is open to collaboration, and include all academic sites across Canada.   

The Convalescent Plasma Trial
(CONCOR-KIDS)

ConCoR-Kids is a clinical trial to understand whether a new treatment for COVID-19, convalescent plasma, works and is safe for children with COVID-19.

It is a randomized, multicentered, open-label Phase 2 clinical trial of the safety and efficacy of human Coronavirus-immune convalescent plasma for the treatment of COVID-19 disease in hospitalized children. This study is conducted because there is currently no proven treatment for COVID-19. The usual care for children with COVID-19 is supportive therapy, to make children as comfortable as possible.

bottom of page